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Objective. Dose adjustment for induction of ovulation is one of the most important problem. Methods. In a prospective
interventional study, 44 clomiphene-resistant infertile patients (113 cycles) were selected from the Abolfazl Infertility Clinic of
Bushehr University of Medical Sciences. Letrozole was given orally in a dose of 2.5mg, 5mg, and 7.5mg, respectively. If the
patient displayed no response, the dosage was increased. Results. In this patients ovulation occurred in 50 cycles (44.24%), clinical
pregnancy rate according to number of cycles was 23.89% (27 of 113 cycles) and according to the number of patients was 61.36%
(27 of 44 patients). In the 2.5, 5, and 7.5 groups, follicles occurred in 22.9%, 42.1%, and 85.18% of cycles, and pregnancy rate
was 14.58%, 28.94% and, 33.33%, respectively. Conclusions. It is better to administer Letrozole at a lower dosage to prevent
complications and increase the dose based on sonographic results antral follicular count, anti-Mu¨llerian hormone, LH/FSH, and
estradiol.
1. Introduction
Letrozole is an eﬀective treatment for anovulatory infertile
women. Letrozole appears not to have any adverse eﬀects
on the endometrium which is frequently associated with
clomiphene citrate during ovulation induction [1, 2]. Many
researchers have tried letrozole for ovulation induction in
diﬀerent methods [3–9]. Letrozole induced fewer mature
follicles that can decrease multiple-pregnancy rate and risk of
ovarian hyperstimulation syndrome. Therefore, the letrozole
as the first-line drug of ovulation-induction agents in poly-
cystic ovarian syndrome (PCOS) patients can be acceptable
[10]. Segawa et al. have accepted letrozole and clomiphene
to have the same eﬀect in pregnancy outcome in PCOS
patients although letrozole is not toxic and does not have any
significant congenital anomaly associations [11–13]. In this
study we have recommended letrozole in serial doses of 2.5,
5, and 7.5mg in each cycle in clomiphene citrate-resistant
infertile women with PCOS. The main interest of this paper
is the assessment of eﬃcacy and complication of letrozole
in follicular size and number, pregnancy rate, abortion,
endometrial thickness, and cumulative pregnancy rates in a
clinical trial of clomiphene citrate-resistant patients.
2. Materials and Methods
In this prospective intervention, we studied Abolfazle Clinic’s
outpatients of the Bushehr University of Medical Sciences in
Iran who referred between January 1, 2008, and December
30, 2010. The study was approved by the institutional ethics
committee of the Bushehr University of Medical Sciences,
and all patients were required to provide written informed
consent before the study commenced. Inclusion criteria are
as follows. The study group consisted of polycystic ovarian
syndrom (PCOS) patients diagnosed according to the Rot-
terdam criteria [1]. We defined clomiphene citrate (Clomid,
Iran Hormone, Tehran, Iran) resistance as failure to achieve
adequate follicular maturation after consumption of 3 cycles
2 Obstetrics and Gynecology International
of cc at 150mg/day, determined by serial estradiol monitor-
ing and sonography [1]. Patients resistant to clomiphene cit-
rate became candidates for letrozole (Femara, Novartis, QC,
Canada) consumption at the step-up of the protocol. Patients
information was recorded in Table 1. Exclusion criteria
were abnormal thyroid function test, hyperprolactinoma,
galactorrhea, male-factor infertility, tubal and uterine causes
of infertility (hysterosalpingography), abnormal response in
progesterone challenge test which implies no endogenous
estrogen production, FSH > 10, poor patient compliance
or complications with treatment. The required information
was gathered through demographic and infertility interviews
using an information list. Each patient was followed for
6 sessions. Estradiol levels (E2) were measured using the
ELISA method by RAYTO set and DIAPLUS kit before
the administration of HCG. Serial sonography (Hoda 4000,
Japan) was conducted from the 10th day of menstruation
and depended on follicular size (18–24mm) from which
HCG (human chorionic gonadotropin, Pregnyl, Organon,
Oss, The Netherlands) was administered. There were 3
steps in which we prescribed letrozole. In all cases, daily
administration began on the 3rd day of the menstrual
cycle through to the 7th day (totalling 5 days). In the
first step we prescribed letrozole at a dose of 2.5mg (one
tablet). Normal follicular size and endometrial thickness
were considered 18–24mm and 6mm or more, respectively,
[1]. If the follicle was deemed not acceptable, the dose
of letrozole was increased at the next cycle. At the sec-
ond and third steps we prescribed letrozole at a dose of
5mg daily and 7.5mg/day, respectively, and according to
patient’s response, repeated the same dose. In the current
study we tested the hypothesis that prescribing letrozole
as an ovulation induction agent in infertile women would
increase pregnancy rate, ovulation, and follicle number. The
primary outcome measure was normal follicular size, and
the secondary outcome measure was the clinical pregnancy.
Clinical pregnancy was considered as the presence of a
gestational sac with fetal heart activity. Letrozole tablets
were prescribed by an experienced nurse who thoroughly
explained the method of use to the patients. Sonography
was done by an experienced radiologist. Statistical analysis
was performed by the Statistical Package for Social Science
version 11.5 for windows (SPSS Inc., Chicago, IL, USA). The
data was analyzed by student’s t-test and chi-squared test for
linear trend and comparing proportions. A P value of <0.05
was considered to be statistically significant.
3. Results
Demographic information was described in Table 1. These
44 patients had received Clomid in 3 sessions (150mg), and
their sonography results did not show any dominant follicle
in serial sonography and were known as clomiphene citrate
resistant. According to the flow chart (Figure 1), treatment
was started. Number of follicles was summarized in Table 2.
There was a significant linear relationship between letrozole
dosage and follicular number (χ2 for linear trend: 25.6, P <
0.0001), and this trend was significant in each step (χ2 for
linear trend: 11.48, P = 0.005) (Table 2). Complications
Table 1: Patient and cycle characteristics.
Characteristics Mean ± SD Range
Age (years) 26.67± 5.14 18–39
BMI (kg/m2) 25.8± 2.4 19.3–29.85
Duration of infertility (years) 3.5± 0.82 2–8
Basal FSH (mIU/mL) 5.95± 1.48 <10
Basal LH (mIU/mL) 7.12± 2.2 <12
Basal Esteradiol (pg/mL) 45.98± 21.33 25–75
Basal TSH (μIU/mL). 2.18± 1.4 0.88–4
Basal prolactin (ng/mL) 20.14± 2.89 <24
DHEAS (Ug/dL) 220± 130 35–430
Testosterone (ng/mL) 0.48± 0.3 0.1–1.8
Table 2: Number of follicles in step-up protocol.
Dosage One follicle Multifollicles
Letrozole 2.5mg 10 (83.33%) 2 (16.66%)
Letrozole 5mg 11 (68.75%) 5 (31.25%)
Letrozole 7.5mg 15 (65.21%) 8 (34.78%)
χ2 for linear trend: 25.6, P < 0.0001.
Table 3: Complication of letrozole in step-up protocol.
Dosage AUB Ovarian cyct
Letrozole 2.5mg 2.08% —
Letrozole 5mg 2.63% 2.63%
Letrozole 7.5mg 14.61% 3.7%
χ2 for linear trend: 6.38, P < 0.011.
Table 4: characteristics of letrozole cycles.
Variable
Letrozole
groups
Mean ± SD
Letrozole
total cycle
Follicular development (mm) 20.3± 1.89 113
Serum E2 one day of HCG (pg/mL) 120± 15.5 113
Pregnancy/cycles 27 (23.89%) 113
Pregnancy/total patients 27 (61.36%) 113
were presented in Table 3. There was a significant linear trend
between Letrozole dosage and its complications (χ2 for linear
trend: 6.38, P < 0.011) (Table 3). Characteristic of letrozole
cycle was showed in Table 4.
4. Discussion
In this study clomiphene citrate-resistant patient had diﬀer-
ent response to letrozole in a way that 44.24% of the cycles
had normal follicles and 23.89% of them resulted in preg-
nancy. Increasing the dosage can improve the chance of ovu-
lation and pregnancy. Only 7 (15.9%) patients with 2.5mg
letrozole daily became pregnant while 11 patients were
pregnant by increasing the dosage to 5mg, and, among those
who did not respond to these dosages, 9 patients became
pregnant by increasing it to 7.5mg. About 61.36% of the
patients became pregnant with letrozole although letrozole is
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Inclusion criteria:
polycystic ovarian syndrome
clomiphene resistance
Exclusion criteria:
mechanical infertility
male infertility
specific endocrine abnormality
44 patients (48 cycles) received 2.5 mg∗ letrozole
Normal follicles: 11 patients (22.9%)
Pregnancy rate: 7 patients (15.9%)
33 patients (38 cycles) received 5 mg letrozole
Normal follicles: 16 patients (42.1%)
Pregnancy rate: 11 patients (33.3%)
Loss of followup:
4 patients
15 patients (27 cycles) received 7.5 mg letrozole
Normal follicles: 23 patients (85.18%)
Pregnancy rate: 9 patients (60%)
Loss of followup:
7 patients
No response to letrozole:
6 patients
Figure 1: Flow chart of patient’s treatment. ∗mg (milligram).
more expensive than clomid but cheaper than gonadotropins
and so is more cost eﬀective. The metformin-clomiphene
citrate combination was seen to increase the ovulatory and
pregnancy rate when compared with CC alone. Metformin
increased the ovulatory rate in clomiphene citrate failures,
also implying increased sensitivity to clomiphene citrate
[14]. Akbary-Asbagh et al. and Begum et al. suggest letrozole
as an eﬀective treatment for clomiphene citrate-resistant
(PCOS) patients [15, 16]. Two of 113 cycles resulted in twins;
increasing the dosage improved the chance of two follicles
in one cycle. In the first step, like Akbary-Asbagh et al. and
Begum et al. study [15, 16], all the cycles had one follicle,
but 31.25% and 30.43% of cycles had two follicles in 5mg
and 7.5mg Letrozole regimen, respectively, even one patient
had 3 follicles in a cycle. In Mitwally et al.’s study, for all
PCO patients with a serial increase of letrozole dosage (set-
up protocol) the same results were confirmed which may
be due to the long-term inhibition of estrogen levels (E2)
[17]. When a patient responds to clomiphene citrate, the
E2 will increase considerably which will be greater than
when she receives Letrozole [2, 4]. Because of clomiphene
citrate resistance, E2 levels do not increase by clomiphene
citrate consumption, and beside ovulation its level will be
less than the acceptable level in letrozole groups [6]. Basal
testosterone level is a good marker for pregnancy outcome
and quantity of dominant follicles on HCG day in women
with reduced ovarian reserve but not in women with normal
range of serum FSH [18]. Letrozole is an eﬀective ovulation
induction drug in elevated-BMI women [19]. We had not
any correlation between BMI, basal testosterone, LH/FSH,
and number of mature follicle because according to inclusion
criteria all of the patients had normal testosterone level,
BMI, and LH/FSH ratio. The chance of AUB increased from
2.08% with 2.5mg letrozole daily to 2.63% with 5mg daily
and 14.8% in the 7.5mg regimen. No change was found in
endometrial thickness according to the Cortines study [6]. So
AUB could be due to a decrease in estrogen levels. Given these
findings, it is required that more investigations be conducted
with estrogen drugs like conjugated estrogens which can
prevent AUB in cases with additional letrozole dosage.
Letrozole can block estrogen (E) production, consequential
in decreased negative feedback of E on pituitary for FSH
secretion. Bentov et al., prove that a ratio of cycle day 7
to cycle day 3 postletrozole FSH level >1.5 is related with
poor ovarian response. Letrozole challenge test can be a
prediction of ovarian response [20]. We suggest that higher
pregnancy rates during letrozole treatment can be achieved
if antral follicular count, anti-Mu¨llerian hormone, LH/FSH,
and estradiol are checked and good patient selection is done
[1]. The good pregnancy results and low multiple gestation
rate of 2.5mg letrozole for induction of ovulation is hopeful
for letrozole user as a first-line drug [12]. The chances
of multigestational pregnancy increases by increasing the
number of follicles in a cycle which implies an appropriate
response to letrozole. Cumulative pregnancy rates were
considerable in clomiphene citrate resistant patients, but the
pregnancy rate was not significantly diﬀerent between the
2.5, 5, and 7.5mg regimens while complications (multiges-
tational pregnancy risk, irregular bleeding, and ovarian cyst)
increased by dosage. Delivery rate was 25 live birth/cycles
(22.12%) due to 2 abortions during the study.
5. Conclusion
Finally it is concluded that in Clomid-resistant patients, it is
better to start letrozole with the lower dosage to preventmore
complications and increase dosage based on the sonographic
results, antral follicular count, anti-Mu¨llerian hormone, LH/
FSH, and estradiol.
4 Obstetrics and Gynecology International
Acknowledgments
The authors are grateful to the Bushehr University ofMedical
Sciences, the Management of Research Aﬀairs, that approved
the proposal, and this data was collected fromMr. Maneshi’s
thesis.
References
[1] J. Brown, C. Farquhar, J. Beck, C. Boothroyd, and E. Hughes,
“Clomiphene and anti-oestrogens for ovulation induction in
PCOS,” Cochrane Database of Systematic Reviews, no. 4, Article
ID CD002249, 2009.
[2] M. F. M. Mitwally and R. F. Casper, “Use of an aromatase
inhibitor for induction of ovulation in patients with an
inadequate response to clomiphene citrate,” Fertility and
Sterility, vol. 75, no. 2, pp. 305–309, 2001.
[3] A. Requena, J. Herrero, J. Landeras et al., “Use of letrozole in
assisted reproduction: a systematic review and meta-analysis,”
Human Reproduction Update, vol. 14, no. 6, pp. 571–582, 2008.
[4] M. R. Begum and A. Begum, “Letrozole vs clomiphene
citrate in induction of ovulation in polycystic ovarian disease
(PCOD),” Fertility and Sterility, vol. 86, no. 3, supplement,
S408 pages, 2006.
[5] M. F. M. Mitwally and R. F. Casper, “Single-dose adminis-
tration of an aromatase inhibitor for ovarian stimulation,”
Fertility and Sterility, vol. 83, no. 1, pp. 229–231, 2005.
[6] A. Cortinez, I. De Carvalho, D. Vantman, F. Gabler, G. Iniguez,
andM. Vega, “Hormonal profile and endometrial morphology
in letrozole-controlled ovarian hyperstimulation in ovulatory
infertile patients,” Fertility and Sterility, vol. 83, no. 1, pp. 110–
115, 2005.
[7] H. Holzer, R. Casper, and T. Tulandi, “A new era in ovulation
induction,” Fertility and Sterility, vol. 85, no. 2, pp. 277–284,
2006.
[8] H. Al-Fozan, M. Al-Khadouri, S. L. Tan, and T. Tulandi, “A
randomized trial of letrozole versus clomiphene citrate in
women undergoing superovulation,” Fertility and Sterility, vol.
82, no. 6, pp. 1561–1563, 2004.
[9] T. Tulandi and A. H. DeCherney, “Limiting access to letrozole-
is it justified?” Fertility and Sterility, vol. 88, no. 4, pp. 779–780,
2007.
[10] U. Bayar, M. Basaran, S. Kiran, A. Coskun, and S. Gezer,
“Use of an aromatase inhibitor in patients with polycystic
ovary syndrome: a prospective randomized trial,” Fertility and
Sterility, vol. 86, no. 5, pp. 1447–1451, 2006.
[11] T. Segawa, K. Shinohara, O. Miyauchi, S. Kawachiya, Y.
Takehara, and O. Kato, “Comparison of pregnancy outcome
in PCOS patients after infertility treatment with letrozole or
clomiphene citrate,” Fertility and Sterility, vol. 90, supplement,
p. S484, 2008.
[12] M. F. Mitwally, M. M. Biljan, and R. F. Casper, “Pregnancy
outcome after the use of an aromatase inhibitor for ovarian
stimulation,” American Journal of Obstetrics and Gynecology,
vol. 192, no. 2, pp. 381–386, 2005.
[13] T. Tulandi, J. Martin, R. Al-Fadhli et al., “Congenital mal-
formations among 911 newborns conceived after infertility
treatment with letrozole or clomiphene citrate,” Fertility and
Sterility, vol. 85, no. 6, pp. 1761–1765, 2006.
[14] P. Dasari and G. Pranahita, “The eﬃcacy of metformin and
clomiphene citrate combination compared with clomiphene
citrate alone for ovulation induction in infertile patients with
PCOS,” Journal of Human Reproductive Sciences, vol. 2, no. 1,
pp. 18–22, 2009.
[15] F. Akbary-Asbagh, Z. Heidar, F. Frozan-Fard et al., “Evaluation
of letrozole therapeutic eﬀect in infertile women,” Acta Medica
Iranica, vol. 45, no. 3, pp. 199–203, 2007.
[16] M. R. Begum, E. Quadir, A. Begum, R. A. Begum, and M.
Begum, “Role of aromatase inhibitor in ovulation induction
in patients with poor response to clomiphene citrate,” Journal
of Obstetrics and Gynaecology Research, vol. 32, no. 5, pp. 502–
506, 2006.
[17] M. F. Mitwally, T. Said, A. Galal et al., “Letrozole step-up
protocol: a successful superovulation protocol,” Fertility and
Sterility, vol. 89, no. 4, supplement, pp. S23–S24, 2008.
[18] Y. Qin, Z. Zhao, M. Sun, L. Geng, L. Che, and Z. J. Chen,
“Association of basal serum testosterone levels with ovarian
response and in vitro fertilization outcome,” Reproductive
Biology and Endocrinology, vol. 9, article 9, 2011.
[19] K. K. McKnight, J. L. Nodler, J. J. Cooper Jr., V. R. Chapman,
S. P. Cliver, and G. W. Bates Jr., “Body mass index-associated
diﬀerences in response to ovulation induction with Letrozole,”
Fertility and Sterility, vol. 96, no. 5, pp. 1206–1208, 2011.
[20] Y. Bentov, E. Burstein, N. Esfandiari, and R. F. Casper, “Use
of letrozole challenge test to adjust gonadotropin dose in non-
down-regulated cycles,” Fertility and Sterility, vol. 95, no. 8, pp.
2492–2493, 2011.
